The UK Competition Authority publishes its decision finding a pharmaceutical company guilty of excessive pricing on thyroid tablets (Advanz)

On 15 December 2021, the UK Competition and Markets Authority (“CMA”) published the non-confidential version of its decision in Advanz Pharma, which provides further insight into its approach to dealing with excessive pricing. As reported earlier (See Michael Clancy, Samuel Hall, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The UK Competition Authority imposes fines totaling more than £101 million on a pharmaceutical company for charging excessive and unfair prices for liothyronine tablets (Advanz), 29 July 2021, e-Competitions July 2021, Art. N° 101804), on 29 July 2021, the CMA imposed fines totalling more than £101 million on Advanz Pharma and the previous owners of the business, Cinven and HgCapital, for charging excessive prices for liothyronine tablets – a treatment for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Barbara Monti, The UK Competition Authority publishes its decision finding a pharmaceutical company guilty of excessive pricing on thyroid tablets (Advanz), 15 December 2021, e-Competitions December 2021, Art. N° 104607

Visites 241

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues